For Healthcare Professionals

AMX0035 and Progressive Supranuclear Palsy

clipboard-pencil

About the study

A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Male or female 40 to 80 years of age, inclusive
  2. Diagnosis of possible or probable PSP Richardson Syndrome
  3. Presence of PSP symptoms for <5 years
  4. Score of <40 on the total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS)
  5. Able to walk independently or with minimal assistance
  6. Minimum score of 24 on the Mini Mental State Examination (MMSE)
  7. Must reside outside a skilled nursing facility or dementia care facility at the time of screening. Residence in an assisted living facility is allowed
  8. Must have a study partner willing to attend study visits and provide information on participant's status
  9. Capable of providing informed consent
  10. Capable and willing to comply with trial procedures including visits to the trial clinic, visit requirements and treatment schedule, including MRI scans
  11. Female participants of childbearing potential must agree to use effective birth control for the duration of the study and for 6 months after last dose of study drug.
  12. Males must agree to use effective birth control method for the duration of the study and for 6 months after the last dose of study drug. Men must not plan to donate sperm.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Require use of a feeding tube
  2. Evidence of any neurological disorder that could explain signs of PSP
  3. Evidence of any clinically significant neurological disorder other than PSP, including significant cerebrovascular abnormalities, vascular dementia, motor neuron disease or ALS, Huntington's disease, normal pressure hydrocephalus, brain tumor, seizure disorder, multiple sclerosis, or known structural brain abnormalities.
  4. History of autosomal dominant PSP due to a Microtubule Associated Protein Tau (MAPT) mutation
  5. History of an autosomal dominant mutation associated with Frontotemporal Lobar Degeneration (FTLD)
  6. Prior or current diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
  7. Presence of unstable psychiatric disease, cognitive impairment (e.g., major cognitive dysfunction), dementia, major depression, or substance abuse that would impair ability of the participant to provide informed consent and follow instructions
  8. Abnormal liver function
  9. Renal insufficiency
  10. Ongoing anemia
  11. History of Class III/IV heart failure per New York Heart Association (NYHA)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +44 (808) 1642604Email iconEmail Study Center

Study Details


Contition

Progressive Supranuclear Palsy,PSP,Neurodegenerative Diseases,Atypical Parkinsonism

Age

40 - 80

Phase

PHASE2/PHASE3

Participants Needed

110

Est. Completion Date

Nov 30, 2029

Treatment Type

INTERVENTIONAL


Sponsor

Amylyx Pharmaceuticals Inc.

ClinicalTrials.gov NCT Identifier

NCT06122662

Study Number

A35-009

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.